CHRNA7 and neoplasm: Therefore, these tumor-promoting actions as well as pro-fibrotic actions via α7nAChRs could be serious barriers to employing α7nAChR agonists to attenuate inflammation in chronic inflammatory diseases such as COPD and asthma, which require continuous drug administration.